Loading
A phase 1 trial of Rezatapopt run by PMV Pharmaceuticals, Inc, now recruiting.
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. is a phase 1 interventional study registered as NCT07372625 by PMV Pharmaceuticals, Inc, with 14 participants planned, started 2026-02-04, primary completion expected 2027-03. Conditions recorded: TP53 Y220C Mutation, Advanced Solid Tumors. Interventions recorded: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt.
Shares Rezatapopt, PMV Pharma and the tag pipeline.
Shares Rezatapopt, PMV Pharma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/